Astellas
-
Astellas Plots Near-Term Moves to Execute Long-Term Vision in Gene Therapy
Astellas has become an active player in gene therapy. MedCity News caught up with company executive Richard Wilson, who explained Astellas’s strategy, the clinical holds on its two most advanced programs, and the rationale behind its recent gene therapy deals.
-
Astellas takes a stake in Taysha and gets a chance at next big gene therapy buyout
Astellas has purchased an equity stake in Taysha Gene Therapies in a $50 million deal that gives it an option to license the company’s two lead gene therapy candidates. The Japanese pharmaceutical giant also gains the option to buy its new partner outright depending on clinical and regulatory developments expected in the coming year.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
$200M investment to advance clinical programs for Ambrx
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
-
Amgen, Astellas to pay government nearly $125M to resolve copay kickback allegations
The deal struck Thursday follows similar settlements between the Department of Justice and three other drugmakers. The department alleged that the companies started copay-assistance funds that violated anti-kickback laws.
-
‘Under-the-radar’ companies could become hot acquisition targets in 2018
Nearly a dozen companies were identified in a report as potentially attractive for buyouts by larger firms. Japanese companies could be big players.
-
Startups: Astellas on M&A prowl to boost drug pipeline
Astellas is on the lookout for new, early stage drugs to boost its pipeline – particularly because later-stage assets still have overinflated valuations.
-
Top Story, Devices & Diagnostics
Medtronic highlights evolving diabetes strategy, Astellas pairs with Swiss biotech in $760M deal (Morning Read)
Medtronic highlighted a shift in its diabetes strategy towards smaller deals in the latest quarterly earnings report.
-
Medivation, Astellas prostate cancer pill recommended for Britain’s NHS
LONDON (Reuters) – Britain’s healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service.
The draft guidance is conditional on Xtandi being provided at an undiscl…
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
